Ariela Noy, MD, discusses the next phase of a trial with devimistat in patients with relapsed/refractory Burkitt lymphoma.
Ariela Noy, MD
Advertisement
Articles by Ariela Noy, MD
Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt LymphomaPublished: December 19th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5